Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on oncology therapeutics that reached public markets through a de-SPAC merger with LifeSci Acquisition Corp, a blank-check vehicle sponsored by LifeSci Capital LLC that completed its IPO in 2020. The business combination closed in early 2021, listing Vincerx on Nasdaq under the VINC ticker. On April 28, 2025, the company filed a Form 25 with the SEC — the statutory notice of removal from exchange listing and deregistration under Section 12(b) of the Securities Exchange Act — marking the end of its tenure as a nationally listed public company. Sign up at SpacDesk for full filing history, status tracking, and deal data on VINC and the broader SPAC universe.